Jazz Pharmaceuticals plc
JAZZ- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001232524
In the last 90 days, Jazz Pharmaceuticals plc insiders filed 0 open-market purchases and 6 sales; 648 institutions reported holding it in 13F filings for Q2 2026, worth $15.5B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $24.4M in total
- 6
- 13F holdersQ2 2026, +78 vs. previous quarter
- 648
- 13F valueReported value at the end of Q2 2026
- $15.5B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding JAZZ, Q2 2026
No superinvestor reported holding JAZZ at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Jazz Pharmaceuticals plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 14, 2026 (view filing)6:38 PM ET | Sep 10 | 4 days | Patil Neena MEVP & Chief Legal Officer | SSale | −1.20K | $240.94 | −$289.1K | −2.5%47.7K after | 10b5-1 |
| Sep 10, 2026 (view filing)4:33 PM ET | Sep 8 | 2 days | Gala Renee DPresident & CEO | SSale | −2.00K | $243.03 | −$486.1K | −1.4%143.4K after | 10b5-1 |
| Sep 2, 2026 (view filing)5:03 PM ET | Sep 1 | 1 day | Cozadd Bruce CDirector | SSale | −6.00K | $250.13 | −$1.50M | −1.7%351.9K after | 10b5-1 |
| Aug 31, 2026 (view filing)6:45 PM ET | Aug 27 | 4 days | Iannone RobertEVP, Global Head of R&D & CMO | SSale | −76.9K | $249.70 | −$19.2M | −53.9%65.7K after | 6 lots10b5-1 |
| Aug 5, 2026 (view filing)4:33 PM ET | Aug 3 | 2 days | Cozadd Bruce CDirector | SSale | −6.00K | $252.98 | −$1.52M | −1.6%360.7K after | 10b5-1 |
| Jul 6, 2026 (view filing)6:23 PM ET | Jul 1 | 5 days | Cozadd Bruce CDirector | SSale | −6.00K | $240.47 | −$1.44M | −1.6%366.7K after | 10b5-1 |
| Jun 17, 2026 (view filing) | Jun 15 | 2 days | Smith Mark DouglasDirector | SSale | −1.16K | $230.55 | −$266.7K | −10.7%9.68K after | 10b5-1 |
| Jun 12, 2026 (view filing) | Jun 10 | 2 days | Patil Neena MEVP & Chief Legal Officer | SSale | −1.20K | $231.83 | −$278.2K | −2.3%51.5K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1 | 2 days | Cozadd Bruce CDirector | SSale | −6.00K | $235.12 | −$1.41M | −1.6%372.7K after | 10b5-1 |
| Jun 1, 2026 (view filing) | May 28 | 4 days | Pearce SamanthaEVP, Chief Commercial Officer | SSale | −6.91K | $235.41 | −$1.63M | −12.1%50.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Jazz Pharmaceuticals plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5,968,603 | $1.44B | 0.02% | +376,903+6.7% | Added |
| FMR LLC | 4,609,326 | $1.11B | 0.05% | +2,333,564+102.5% | Added |
| Vanguard Portfolio Management LLC | 3,036,213 | $731.6M | 0.03% | +52,971+1.8% | Added |
| Vanguard Capital Management LLC | 2,729,650 | $657.8M | 0.01% | +81,317+3.1% | Added |
| Capital World Investors | 2,697,610 | $650.0M | 0.08% | +24,234+0.9% | Added |
| LSV Asset Management | 2,275,145 | $548.2M | 0.99% | −111,695−4.7% | Reduced |
| Franklin Resources Inc | 2,040,250 | $491.6M | 0.11% | +81,310+4.2% | Added |
| State Street Corp | 1,999,816 | $481.9M | 0.01% | +108,170+5.7% | Added |
| Dimensional Fund Advisors LP | 1,713,592 | $412.9M | 0.07% | −181,623−9.6% | Reduced |
| Fuller & Thaler Asset Management, Inc. | 1,638,544 | $394.8M | 1.08% | −37,598−2.2% | Reduced |